ASCOT: a tale of two treatment regimens: odds are that it's hype

Comment

Martin G Duerden. BMJ. 2005.

. 2005 Oct 29;331(7523):1022-3.

doi: 10.1136/bmj.331.7523.1022-b.

No abstract available

Comment on

The PROGRESS trial three years later: time for more action, less distraction.
Macmahon S, Neal B, Rodgers A, Chalmers J. Macmahon S, et al. BMJ. 2004 Oct 23;329(7472):970-1. doi: 10.1136/bmj.329.7472.970. BMJ. 2004. PMID: 15499117 Free PMC article. No abstract available.
How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
Freemantle N. Freemantle N. BMJ. 2005 Oct 8;331(7520):836-8. doi: 10.1136/bmj.331.7520.836. BMJ. 2005. PMID: 16210286 Free PMC article. Review.
ASCOT: a tale of two treatment regimens.
McDougall C, Brady AJ, Petrie JR. McDougall C, et al. BMJ. 2005 Oct 15;331(7521):859-60. doi: 10.1136/bmj.331.7521.859. BMJ. 2005. PMID: 16223801 Free PMC article. No abstract available.

1. McDougall C, Brady AJB, Petrie JR. ASCOT: a tale of two treatment regimens. BMJ 2005;331: 859-60. (15 October.) - PMC - PubMed
1. Dickerson JC, Hingorani AD, Ashby MJ, Palmer CR, and Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999:353: 2008-13. - PubMed
1. National Institute for Health and Clinical Excellence. Management of hypertension in primary care. Clinical guideline 18. London: NICE: 2004.
1. Freemantle N. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? BMJ 2005;331: 836-8. (8 October.) - PMC - PubMed
1. MacMahon S, Neal B, Rodgers A, Chalmers J. The PROGRESS trial three years later: time for more action, less distraction. BMJ 2004;329: 970-1. - PMC - PubMed